RAC1 and cancer: Although, it is yet to be determined whether 1A-116 is limited to targeting the Rac1-P-Rex1 binding interface or whether it interferes with other Rac1-GEF complexes, 1A-116 represents a promising Rac1 selective inhibitor that might be of clinical relevance, particularly in cancer.